MYPT1 (phospho-T696) polyclonal antibody 
Datasheet
COA
MSDS
SHIP
Product Name :
MYPT1 (phospho-T696) polyclonal antibody Background :
Myosin phosphatase target subunit 1 (MYPT1), also called Myosin-binding subunit of Myosin phosphatase, is one of the subunits and an integral component of the Myosin phosphatase. Myosin phosphatase regulates the interaction of Actin and Myosin downstream of the guanosine triphosphatase Rho, which inhibits Myosin phosphatase through the action of Rho-kinase. MYPT1 promotor contains one Sp1 transcription factor binding site, suggesting that MYPT1 is a housekeeping gene. Myotonic dystrophy protein kinase phosphorylates MYPT1 at Tyrosine 654 to regulate Myosin II phosphorylation. Inhibition of Myosin light chain phosphatase results in Ca2+ sensitization of smooth muscle contraction. This inhibition is modulated through phosphorylation of MYPT1 by a ZIP-like kinase, which associates with MYPTI and phosphoryl-ates the inhibitory site in smooth muscle. The phosphorylation of MYPT1 by protein kinase C results in altered dephosphoryation of Myosin by attenuating the binding of protein phosphatase 1 catalytic subunit (PP1c) and the phosphorylated Myosin light chain to MYPT1. PP1c interacts with at least four binding sties on the amino-terminus of MYPT1. Product :
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
MYPT1 (phospho-T696) polyclonal antibody detects endogenous levels of MYPT1 protein only when phosphorylated at T696. Immunogen :
Synthetic peptide derived from human MYPT1 around the phosphorylation site of T696. Conjugate :
Unconjugated Modification :
Phosphorylation
MYPT1 (phospho-T696) polyclonal antibody Background :
Myosin phosphatase target subunit 1 (MYPT1), also called Myosin-binding subunit of Myosin phosphatase, is one of the subunits and an integral component of the Myosin phosphatase. Myosin phosphatase regulates the interaction of Actin and Myosin downstream of the guanosine triphosphatase Rho, which inhibits Myosin phosphatase through the action of Rho-kinase. MYPT1 promotor contains one Sp1 transcription factor binding site, suggesting that MYPT1 is a housekeeping gene. Myotonic dystrophy protein kinase phosphorylates MYPT1 at Tyrosine 654 to regulate Myosin II phosphorylation. Inhibition of Myosin light chain phosphatase results in Ca2+ sensitization of smooth muscle contraction. This inhibition is modulated through phosphorylation of MYPT1 by a ZIP-like kinase, which associates with MYPTI and phosphoryl-ates the inhibitory site in smooth muscle. The phosphorylation of MYPT1 by protein kinase C results in altered dephosphoryation of Myosin by attenuating the binding of protein phosphatase 1 catalytic subunit (PP1c) and the phosphorylated Myosin light chain to MYPT1. PP1c interacts with at least four binding sties on the amino-terminus of MYPT1. Product :
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
MYPT1 (phospho-T696) polyclonal antibody detects endogenous levels of MYPT1 protein only when phosphorylated at T696. Immunogen :
Synthetic peptide derived from human MYPT1 around the phosphorylation site of T696. Conjugate :
Unconjugated Modification :
Phosphorylation
-
Western blot (WB) analysis of p-MYPT1 (T696) polyclonal antibody at 1:500 dilution Lane1:HEK293T whole cell lysate(40ug) Lane2:HEK293T treated with PMA (60ng/ml, 10min) whole cell lysate (40ug) Lane3:HEK293T treated with UV (4h) whole cell lysate (40ug)
Rho Kinase Inhibitor, Fasudil, Attenuates Contrast‐induced Acute Kidney Injury
PMCID: Pubmed No.:28929640
The ROCK inhibitor Y-27632 ameliorates blood-spinal cord barrier disruption by reducing tight junction protein degradation via the MYPT1-MLC2 pathway after spinal cord injury in rats
PMCID: Pubmed No.:34634287
Inhibition of Rho‑kinase is involved in the therapeutic effects of atorvastatin in heart ischemia/reperfusion
PMCID: Pubmed No.:32855683
MYPT1 inhibits the metastasis of renal clear cell carcinoma via the MAPK8/N-cadherin pathway
PMCID: Pubmed No.:36106411
RhoA/ROCK1 regulates the mitochondrial dysfunction through Drp1 induced by Porphyromonas gingivalis in endothelial cells
PMCID: Pubmed No.:37278388
Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.
Price/Size :
USD 368/1mg/vial
Tips:
For phospho antibody, we provide phospho peptide（0.5mg) and non-phospho peptide(0.5mg).Describe :
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.Formula:
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.
Storage:
The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C.
Note :
This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.